Literature DB >> 10634394

Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone.

G Binder1, C P Schwarze, M B Ranke.   

Abstract

Point mutations or complete deletions of SHOX, the short-stature homeobox-containing gene on the pseudoautosomal region of the sex chromosomes (Xp22 and Yp11.3), were recently reported in one family with idiopathic short stature and in several families with Leri-Weill syndrome (dyschondrosteosis). The missing SHOX is also thought to attribute to the growth failure in Turner syndrome. For testing the frequency of defects of SHOX in unexplained growth failure and recombinant human GH (rhGH) as a possible growth-promoting agent, we selected 68 children with idiopathic short stature. These probands had heights below -2.0 SD score for age, normal target heights, no significant bone age retardations, no endocrine abnormalities, no skeletal diseases, and no other organic diseases. No mutations were detected by single-strand conformational polymorphism analysis of the PCR-amplified SHOX. The analysis of three microsatellite DNA markers of the pseudoautosomal region, including one located on the 5' untranslated region of SHOX-exon 1, identified a 15-yr-old girl who carried a mutation in the form of a complete SHOX deletion. This girl who had a normal karyotype presented with mild mesomelic shortening of the forearms and lower legs. We treated two children with short stature on the basis of a SHOX point mutation (C674T) with rhGH at a dose of 1.0 IU/kg body weight-week in accordance with the regimen used in Turner syndrome. During the first 12 months of treatment, these two children (5.9- and 8.4-yr-old) showed an excellent growth spurt with a growth rate of 9.5 and 9.4 cm/yr, respectively. Growth of the lower extremities was weaker than in the trunk and arms. Our data suggest that short stature due to SHOX deletions is not a rare entity. Growth-promoting therapy with rhGH was effective with regard to height gain, but a tendency to disproportionate growth was apparent. In cases of unexplained growth failure, especially if associated with any mild skeletal disproportions, genetic analysis of SHOX should be considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634394     DOI: 10.1210/jcem.85.1.6375

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  SHOX gene in Leri-Weill syndrome and in idiopathic short stature.

Authors:  S Bernasconi; S Mariani; C Falcinelli; S Milioli; L Iughetti; A Forabosco
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

Review 2.  SHOX mutations.

Authors:  Raymond L Hintz
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

Review 3.  Turner syndrome and GH treatment: the state of the art.

Authors:  A M Pasquino
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

4.  A novel class of Pseudoautosomal region 1 deletions downstream of SHOX is associated with Leri-Weill dyschondrosteosis.

Authors:  Sara Benito-Sanz; N Simon Thomas; Céline Huber; Celine Huber; Darya Gorbenko del Blanco; Darya Gorbenko Del Blanco; Miriam Aza-Carmona; John A Crolla; Vivienne Maloney; Gudrun Rappold; Jesús Argente; Jesus Argente; Angel Campos-Barros; Valérie Cormier-Daire; Valerie Cormier-Daire; Karen E Heath
Journal:  Am J Hum Genet       Date:  2005-08-15       Impact factor: 11.025

Review 5.  SHOX haploinsufficiency and overdosage: impact of gonadal function status.

Authors:  T Ogata; N Matsuo; G Nishimura
Journal:  J Med Genet       Date:  2001-01       Impact factor: 6.318

6.  Improving clinical diagnosis in SHOX deficiency: the importance of growth velocity.

Authors:  Giulia Genoni; Alice Monzani; Matteo Castagno; Roberta Ricotti; Anna Rapa; Antonella Petri; Deepak Babu; Mara Giordano; Flavia Prodam; Gianni Bona; Simonetta Bellone
Journal:  Pediatr Res       Date:  2017-12-06       Impact factor: 3.756

7.  The Human Pseudoautosomal Region (PAR): Origin, Function and Future.

Authors:  A Helena Mangs; Brian J Morris
Journal:  Curr Genomics       Date:  2007-04       Impact factor: 2.236

Review 8.  SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature.

Authors:  Maki Fukami; Atsuhito Seki; Tsutomu Ogata
Journal:  Mol Syndromol       Date:  2016-03-15

9.  Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.

Authors:  J Paul Frindik; Stephen F Kemp
Journal:  Biologics       Date:  2010-06-24

10.  Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency.

Authors:  Renata C Scalco; Suzana S J Melo; Patricia N Pugliese-Pires; Mariana F A Funari; Mirian Y Nishi; Ivo J P Arnhold; Berenice B Mendonca; Alexander A L Jorge
Journal:  J Clin Endocrinol Metab       Date:  2009-11-19       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.